Helix BioPharma Corp. and Moffitt Cancer Center to Present at the AACR Annual Meeting 2019 in Atlanta

RICHMOND HILL, ONTARIO- Helix BioPharma Corp. (TSX: HBP), (FSE: HBP) (“Helix” or the “Company”), an immuno-oncology company developing innovative drug candidates for the prevention and treatment of cancer, is pleased to announce that together with the Moffitt Cancer Center (“Moffitt”), a poster entitled “Improving survival in pancreatic cancer using Doxorubicin in combination with L-DOS47” will be presented at the American Association for Cancer Research (“AACR”) Annual Meeting 2019 which is taking place on March 29 – April 3, 2019 at the Georgia World Congress Center, Atlanta, Georgia, USA.